This is a working overview of anti-doping analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-09 and is reviewed periodically as new material appears.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
=== Inference === Variant genetic codes used by an organism can be inferred by identifying highly conserved genes encoded in that genome, and comparing its codon usage to the amino acids in homologous proteins of other organisms. For example, the program FACIL infers a genetic code by searching which amino acids in homologous protein domains are most often aligned to every codon. The resulting amino acid (or stop codon) probabilities for each codon are displayed in a genetic code logo. As of January 2022, the most complete survey of genetic codes is done by Shulgina and Eddy, who screened 250,000 prokaryotic genomes using their Codetta tool. This tool uses a similar approach to FACIL with a larger Pfam database. Despite the NCBI already providing 27 translation tables, the authors were able to find new 5 genetic code variations (corroborated by tRNA mutations) and correct several misattributions. Codetta was later used to analyze genetic code change in ciliates.
{\displaystyle \gamma _{yz}=\gamma _{zy}={\frac {\partial u_{y}}{\partial z}}+{\frac {\partial u_{z}}{\partial y}}\quad ,\qquad \gamma _{zx}=\gamma _{xz}={\frac {\partial u_{z}}{\partial x}}+{\frac {\partial u_{x}}{\partial z}}}
The Indigenous peoples saw widespread famine and disease due to the loss of the bison and their traditional hunting lands. The federal government did provide emergency relief, on condition of the Indigenous peoples moving to the reserves. During this time, Canada introduced the Indian Act unilaterally extending its control over the First Nations to education, government and legal rights.
The origin of cells has to do with the origin of life, which began the history of life on Earth. Small molecules needed for life may have been carried to Earth on meteorites, created at deep-sea hydrothermal vents, or synthesized by lightning in a reducing atmosphere. There is little experimental data defining what the first self-replicating forms were. RNA may have been the earliest self-replicating molecule, as it can both store genetic information and catalyze chemical reactions. This process required an enzyme to catalyze the RNA reactions, which may have been the early peptides that formed in hydrothermal vents. Cells emerged around 4 billion years ago. The first cells were most likely heterotrophs. The early cell membranes were probably simpler and more permeable than later ones, with only a single fatty acid chain per lipid. Lipids spontaneously form bilayered vesicles in water, and could have preceded RNA.
Sources: en.wikipedia.org
Among the newly emergent strata were wealthy industrialists and financiers, distinct from the traditional, but still critically important landed aristocracy. The intelligentsia, an educated, professional or business middle class, often originated from lower gentry, landless or alienated from their rural possessions, and from urban people. Many smaller agricultural enterprises based on serfdom did not survive the land reforms. The industrial proletariat, a new underprivileged class, was composed mainly of poor peasants or townspeople forced by deteriorating conditions to migrate and search for work in urban centers in their countries of origin or abroad. Millions of residents of the former Commonwealth of various ethnic groups worked or settled in Europe and in North and South America. Social and economic changes were partial and gradual. The degree of industrialisation, relatively fast-paced in some areas, lagged behind the advanced regions of Western Europe. The three partitions developed different economies and were more economically integrated with their mother states than with each other. In the Prussian Partition, for example, agricultural production depended heavily on the German market, whereas the industrial sector of Congress Poland relied more on the Russian market.
The first White Castle in the far western United States opened at the Casino Royale Hotel & Casino on the Las Vegas Strip on January 27, 2015. This was the first expansion for White Castle into a region outside the Midwest and Northeast in 56 years. On the first day of business, demand for food was so great that the restaurant had to temporarily close for two hours to restock. White Castle Vice President Jamie Richardson said that the store sold 4,000 sliders per hour in its first 12 hours. He was not aware of any similar closing due to unexpected demand in White Castle's 94-year history. A second White Castle location opened in Las Vegas in September 2017 on Fremont Street, a third opened in Jean at the Terrible's Road House in October 2018, a fourth location on Paradise Road in December 2019, and a fifth location in Henderson in June 2022. The Royale Hotel and Henderson locations were closed on March 30, 2026. In September 2015, White Castle began to offer Veggie Sliders with dairy-free buns to provide a vegan option. In December 2015, White Castle announced that chief executive officer (CEO) E.W. "Bill" Ingram III would step down at the end of the year, but continue to be chairman of the board. His daughter, Lisa Ingram, then became the fourth CEO of the company. In 2018, White Castle began offering plant-based meat Impossible Burgers designed to closely mimic the flavor and texture of beef burgers. The first White Castle location in Arizona opened in Scottsdale on October 23, 2019. A second location opened in nearby Tempe on November 28, 2023.
== Awards == Leeman became the first woman elected to the National Academy of Sciences in physiology and pharmacology in 1991. She was elected to the American Academy of Arts and Sciences in 1987. In 1993 she won the FASEB Excellence in Science Award and in 2005 won the Committee on Women in Neuroscience's Mika Salpeter Lifetime Achievement Award.
== Substance Class and Structure == Guanacastepene A belongs to the class of diterpenes, a subclass of terpenes composed of four isoprene units (C20). The guanacastepene skeleton is structurally related to dolastane and neodolabellane diterpene families. The structural elucidation was carried out using two methods: 1H-NMR and 13C-NMR as well as X-ray crystal structure. The NMR spectra at room temperature indicated the presence of two conformers in dynamic equilibrium, and through structural characterization using single-crystal X-ray diffraction techniques, the structure of Guanacastepene A was found to be a tricyclic diterpene with a heavily oxidized longitudinal side and a hydrophobic opposite side. It also revealed that the tricyclic ring of guanacastepene is essentially planar with the exception of C9. Two gauche butane-like conformers are observed around the C9–C10 bond that differ by approximately 0.14 kcal/mol and are separated by an energy barrier of approximately 15 kcal/mol.
== Treatment == Only a small proportion of those with co-occurring disorders actually receive treatment for both disorders. Therefore, it was argued that a new approach is needed to enable clinicians, researchers and managers to offer adequate assessment and evidence-based treatments to patients with dual pathology, who cannot be adequately and efficiently managed by cross-referral between psychiatric and addiction services as currently configured and resourced. In 2011, it was estimated that only 12.4% of American adults with co-occurring disorders were receiving both mental health and addictions treatment. Clients with co-occurring disorders face challenges accessing treatment, as they may be excluded from mental health services if they admit to a substance use problem and vice versa. There are multiple approaches to treat concurrent disorders. Partial treatment involves treating only the disorder that is considered primary. Sequential treatment involves treating the primary disorder first, and then treating the secondary disorder after the primary disorder has been stabilized. Parallel treatment involves the client receiving mental health services from one provider, and addictions services from another. Integrated treatment involves a seamless blending of interventions into a single coherent treatment package developed with a consistent philosophy and approach among care providers. With this approach, both disorders are considered primary.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.